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ABSTRACT OF THESIS

INFLUENCE OF ONCOTYPE DX® ON CHEMOTHERAPY PRESCRIBING IN
EARLY STAGE BREAST CANCER PATIENTS:
A CLAIMS-BASED EVALUATION OF UTILIZATION IN THE REAL WORLD

The decision for adjuvant therapy in women with early stage breast cancer
(ESBC) has historically been guided by the presence or absence of specific
biological markers (hormone and HER2 receptors), age, and extent of nodal
involvement. Oncotype DX® is a validated assay that quantifies protein
expression that can predict the risk of cancer recurrence. This study evaluates if
the use of Oncotype DX® impacts chemotherapy prescribing in ESBC. This
retrospective, cohort study identified patients with ESBC from a large
commercially insured population from January 2007 through June 2009. Patients
were identified as having ESBC by utilizing procedure and diagnosis codes to
indicate that a sentinel lymph node biopsy had been performed. Hormone
receptor status was verified by patients receiving at least one month of hormonal
therapy including: tamoxifen, anastrozole, letrozole, or exemestane. Exclusion
criteria will include patients less than 18 years of age, procedure codes indicating
axillary lymph node dissection, or charges for trastuzumab. The administration of
Oncotype DX® was not found to significantly affect a physician’s decision to
prescribe chemotherapy. However, there were significant regional differences in
Oncotype DX® utilization by region. Future studies should be conducted at a
population level to determine the effects of Oncotype DX®.
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Section 1: Background

It is estimated in 2012 in the United States that there will be approximately 227,000 new cases of
breast cancer in women and approximately 40,000 deaths due to breast cancer.1 Due to earlier
detection, over 90% of breast cancers are diagnosed at an early stage.2 Almost all women (98%)
with early-stage disease can expect a five year survival with modern treatment; however, disease
recurrence is still a threat to long term survival.3 Factors that are considered by clinicians in
designing treatment regimens in early-stage breast cancer (ESBC) are: age, menopausal status of
the patient, stage of disease (including nodal involvement), histologic type and grade, the
presence or absence of hormone receptors, mitotic figure counts, overexpression of human
epidermal growth factor-2 (HER2) receptor, proliferation markers, lymphatic and vascular
channel spread, and mutations in p53. 4 These patient features have been incorporated into
guidelines, for example the St. Gallen5 and the National Comprehensive Cancer Network
consensus (NCCN) guidelines6, or have been integrated into online decision tools like Adjuvant!
Online.7,8 More recently, molecular profiling of the patient’s specific tumor can be performed
with the use of commercially available tests like: Oncotype DX® 9 or MammaPrint10. These
more recent molecular tests and the more historic clinicopathologic characteristics are used by
clinicians to determine if the risk of recurrent disease is high enough to warrant adjuvant systemic
chemotherapy for individual patients. Adjuvant therapy refers to any additional therapy offered
to women after the completion of a primary therapy like surgical resection of the tumor.
Like all other medical treatments, chemotherapy carries a certain risk profile and there is a
potential for serious adverse events to occur, including hospitalization and death. A study
conducted in Brazil, found that 13% of patients (39 of 298 patients) admitted to an oncology unit
were in connection with an adverse drug event. 11 Approximately 50% of these oncology patients
(20 of 39 patients) were admitted with neutropenic fever, and unfortunately 2 of these patients
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died. When focusing just on breast cancer patients in a large claims database, Hasset et al. found
a lower percentage of patients admitted with infection and fever, but the number is still striking at
8.4%.12 Other frequently encountered complications from chemotherapy were: neutropenia
and/or thrombocytopenia (5.5%), anemia (2.2%), constitutional symptoms (2.2%),
dehydration/electrolyte disorder (2.5%), nausea/vomiting/diarrhea (2.4%), and venous
thromboembolism (1.3%). 12 Clearly, chemotherapy is not a benign experience for these women.
Particularly troubling is that a breast cancer patient may be exposed to these potential
complications and yet receive no added benefit from receipt of their chemotherapy. A large
(n=1667) randomized trial that compared tamoxifen to chemotherapy followed by tamoxifen in
node negative breast cancer reported five year disease free survival rates of 81% and 85%,
respectively. Although a positive finding, it is concerning that only 1 out of 25 women treated
with chemotherapy derive benefit. 13 Determining who will or will not benefit from chemotherapy
as part of adjuvant treatment has been extensively studied and continues to be the focus of
investigation.
Oncotype DX® was developed and marketed by Genomic Health of Redwood City, CA, and
became commercially available in 2004. This 21-gene profile measures the expression of 16
cancer genes and 5 reference genes by reverse-transcriptase—polymerase-chain-reaction (RTPCR) to output a continuous Recurrence Score (RS). Oncotype DX® was first validated using
data from NSABP B-14, a large multicenter clinical trial.9 The validation trial was conducted in
node negative stage I or II patients that were hormone receptor positive and treated with
tamoxifen. Patients had to have archived tumor tissue samples available. The individual RS
generated by Oncotype DX® was used to group individuals into risk categories: low risk (RS
<18), intermediate risk (RS 18-30), and high risk (RS >30). The assay was validated by
demonstrating the low risk group (51% of patients) had a 6.8% risk of distant recurrence at 10
years, compared to 14.3% and 30.5% for the intermediate and high risk groups, respectively. 9
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Additionally, Oncotype DX® was validated in a large population-based case-control study using
Kaiser Permanente data from Northern California, which showed the RS predicted 10 year death
rates from breast cancer: 2.8% in the low group, 10.7% in the intermediate group, and 15.5% in
the high group. 14 Next, Oncotype DX® was validated using a similar approach with archived
tumor samples from the NSABP B-20, which delineated patients that would or would not benefit
from adjuvant systemic chemotherapy followed by hormonal therapy. In the low risk patient
population, the 10 year distant recurrence free survival (DRF) was 97% with tamoxifen alone and
96% with chemotherapy followed by tamoxifen. The intermediate group had a non-significant
difference of 2%, which favored tamoxifen monotherapy; while the high risk population showed
a DRF of 61% and 88% favoring the chemotherapy arm. 15 The results of this study are important
because they confirmed that the test could identify the 75% of node negative, hormone receptor
positive patients who will not benefit from chemotherapy. It’s also interesting to note other
studies of the RS from Oncotype DX® have demonstrated the ability to “downgrade” or
reclassify patients into a lower risk category 40-50% of the time, as compared to initial
assessment by a physician16,17 or application of the NCCN guidelines18, thus resulting in avoided
chemotherapy.
The scientific evidence demonstrating that Oncotype DX® accurately predicts clinical outcomes
in women with early-stage, node-negative, hormone receptor positive, HER2 negative disease has
been answered in the previously mentioned trials. However, it is only one of a number of tools
used to guide adjuvant therapy decisions. The focus of this research is to determine how the
Oncotype DX® science has translated into standard practice across the United States. The
primary objective of the current study is to determine how Oncotype DX® is used in a “realworld” setting to guide decision making about adjuvant chemotherapy. Secondary objectives
include overall uptake of use as well as regional differences.
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Section 2: Methods

This was a retrospective, population-based cohort study of ESBC patients that were diagnosed
between January 2007 through June 2009. Patients were selected from a large database of
commercially insured individuals that is representative of the United States. This database
contains de-identified data inclusive of inpatient, outpatient, pharmacy claims, lab results, and
enrollment information for an estimated 15 million unique lives. Overall, this database is
representative of the non-elderly, insurance-carrying population in the US, but it also contains
several hundred thousand Managed Medicaid and Medicare Advantage Members. The
University of Kentucky’s Institutional Review Board granted use of this de-identified database
under a blanketed approval.
Early-stage, node-negative breast cancer patients were eligible if they met the International
Statistical Classification of Diseases and Related Health Problems (ICD-9) and Current
Procedural Terminology (CPT) coding criteria found in Appendix A. Briefly, this included
women greater than 18 years of age, with private insurance, coded with an ICD-9 code indicative
of breast cancer, who received at least one month of hormonal therapy, and underwent a sentinel
lymph node injection and excision. Women had to have this “index” procedure of sentinel node
injection performed between January 1, 2007 through June 30, 2009. Charges for Oncotype
DX® were identified by the test’s unique CPT code (S3854). After January 1, 2006, Oncotype
DX® received its own unique CPT code, which occurred before the start of the the insurance
claims database (personal communication with Genomic Health, Appendix A). The list of
National Drug Codes (NDCs) used to define at least one month of hormonal therapy can be found
in Appendix B.
Women were excluded if they received trastuzumab, which would suggest HER-2 positive
disease, or if they had a more aggressive axillary lymph node dissection or mastectomy, which
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might suggest node-positive disease. These CPT codes and J codes are described in Appendices
A and C, respectively. These inclusion/exclusion criteria were constructed to define the
population of early-stage, hormone receptor positive, node negative disease, to mirror where
Oncotype DX® currently has the most data to support its use.

9,15,19

The primary objective of this study was to determine if a difference existed in the proportion of
patients receiving chemotherapy that had the Oncotype DX® test performed compared to those
that did not undergo the test. Because injectable chemotherapy drugs are billed via J-codes in
medical claims, a separate list of J-codes was created (Appendix C) to determine receipt of
chemotherapy. Having said that, a very small percentage of chemotherapy claims were coded
using NDCs in the database, so Appendix D was also developed to capture all possible
chemotherapeutic agents. Secondary endpoints include: predictors of adjuvant chemotherapy use
and predictors of Oncotype DX® testing. We hypothesize that age, region of the country, and
year of diagnosis will influence these endpoints. The U.S. Census Bureau Regions and Divisions
schema was applied to divide the patients into regions of the country (Appendix E). 20
A question of interest to be examined in exploratory analysis is: what is the median time from
diagnosis to Oncotype DX® test (for those women that had the test administered)? We
hypothesize that age, region of the country, and year of diagnosis will also influence this
endpoint. In particular, we hypothesize that regions of the country that have lower relative
utilization of Oncotype DX® will have a longer time to ordering the test (ie. longer time from
diagnosis to ordering test). Again, the U.S. Census Bureau Regions and Divisions schema was
applied to divide the patients by region of the country (Appendix E). 20
Statistical Analysis
Variables including age, region, adjuvant chemotherapy, whether the Oncotype DX® was
performed, and year of diagnosis were collected and summarized for eligible women. A Chi-
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squared test was used to test the primary hypothesis of the difference in proportions of patients
receiving adjuvant chemotherapy based on whether Oncotype DX® was administered (yes/no).
A multivariate logistic regression, controlling for Oncotype DX®, region, age, and year of
diagnosis, was utilized to study predictors of adjuvant chemotherapy use. A separate
multivariable logistic regression, controlling for region, age, and year of diagnosis, was
implemented to identify predictors of Oncotype DX® testing. Year of diagnosis was included in
both models based on the temporal component of when Oncotype DX® became available in the
US (in 2004) and the time span of the claims database (January 2007 through December 2009).
Receipt of adjuvant chemotherapy was not included in the second logistic regression, as that
event should occur after the Oncotype DX® test is performed, and thus should not influence the
decision to order the test.
Kaplan-Meier curves were utilized to model time to administration of Oncotype DX® (for those
women with a test ordered). Here, the “event” was having the Oncotype DX® test performed.
The median time to Oncotype DX® was calculated as the difference between the date of
Oncotype DX® claim from the date of breast cancer diagnosis (sentinel node biopsy claim).
Curves were stratified by region and year of diagnosis. The log-rank test was applied to detect
for a significant difference between the stratified curves. SAS version 9.1 (Cary, NC) was used
to perform all statistical tests.
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Section 3: Results

Based on ICD-9 codes 114,306 patients were initially identified as having breast cancer. After
inclusion/exclusion criteria of CPT codes and drug classes were applied 2,475 remained with
early-stage, node-negative, hormone receptor positive breast cancer. See Figure 1 for patient
selection pathway. From the cohort selected, all of the patients were female with a mean age of
54.9 years and an age range of 23 to 87 years. Approximately 40% of the patients were from the
South region, with the next highest percentage of 28.9% coming from the Midwest. The patients
were also somewhat evenly distributed throughout the years with approximately 40% from both
2007 and 2008 and the remaining 19% from 2009. See Table 1 for Baseline Demographics when
stratified by receipt of Oncotype DX® (yes/no).

Primary endpoint: Proportion receiving adjuvant chemotherapy by Oncotype DX®
From the cohort of 2,475 patients with early-stage breast cancer, 545 patients (22%) received
adjuvant systemic chemotherapy. 909 patients (36.7%) from the cohort had a claim for Oncotype
DX® during the prescribed time frame. Of these patients with an Oncotype DX® claim, 213
(23.4%) received adjuvant chemotherapy compared to the 332 (21.2%) patients that received
adjuvant chemotherapy from the 1,566 without a claim for Oncotype DX® test (p=0.1965) (see
Figure 2).

Predictors of receiving adjuvant chemotherapy
The average age for women receiving chemotherapy (51.7 years) was almost 4 years younger
than those that did not receive chemotherapy (55.9 years). By region, both the South and West
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received chemotherapy approximately 20% of the time. The Midwest region was noted to have
the highest utilization of chemotherapy, in approximately 27% of women. The Northeast region
had the lowest use of adjuvant chemotherapy in only approximately 12% of women during the
study period. No differences were noted when stratified by year of diagnosis. See Table 2 for
Characteristics of those receiving chemotherapy.
The results of the logistic regression for the odds of receiving chemotherapy, while controlling
for Oncotype DX® administration, region, age, and year of diagnosis can be found in Table 2.
The adjusted odds ratio of receiving chemotherapy based on Oncotype DX® administration,
controlling for all other variables was not statistically significant at 1.06 (95% CI: 0.860 – 1.30).
However, patients located in the Midwest were at a 31% increased odds (OR=1.31, 95% CI:
1.044 – 1.644) of receiving chemotherapy compared to the reference region of the South,
controlling for all other variables. The odds of receiving chemotherapy for a patient in the
Northeast compared to the South, while controlling for all other variables, was 53% lower
(OR=0.47 95% CI: 0.33 – 0.692). There were no significant differences between the West region
and the South. The adjusted odds ratio of receiving chemotherapy decreases by 5% with each
additional year of age (OR=0.95, 95% CI: 0.942 – 0.963). Year of breast cancer diagnosis did
not significantly impact the odds ratio of receiving chemotherapy (2008 vs 2007, OR=0.83, 95%
CI: 0.66 – 1.03; 2009 vs 2007, OR=0.79, 95% CI: 0.6 – 1.04).

Predictors of receiving Oncotype DX®
A secondary objective of this study was to identify any variables that may influence the use of the
Oncotype DX® test as shown in Table 3. By region, the South utilized Oncotype DX® more
frequently in 40% of women, compared to approximately 36% of women in the Northeast and
West, and 33% of women in the Midwest. In 2007, the test was ordered in 27.7% of women,

	
  

8	
  

compared to 41.6% in 2008, to 46.7% in 2009. Again, using the South as the reference region,
the adjusted odds of having the Oncotype test performed in the Midwest was decreased by 29%
(OR = 0.71, 95% CI: 0.574 – 0.868), controlling for all other variables. No statistical differences
were found when comparing the Northeast region or the West region to the South region. The
adjusted odds of receiving the Oncotype DX® test significantly decreased by 4% with each
additional year of age (OR = 0.961, 95% CI: 0.925 – 0.970). The adjusted odds of receiving
Oncotype DX® was significantly increased by 1.9-fold in the year 2008 compared to 2007
(OR=1.9, 95% CI: 1.574 – 2.304) and also significantly increased by 2.4-fold in the year 2009
compared to 2007 (OR=2.419, 95% CI: 1.919 – 3.049).

Exploratory Endpoint: Impact on time to Oncotype DX®
Overall, the Kaplan-Meier estimates for the median time to having Oncotype DX® performed
were 4.4%, 51.7%, 84.9%, and 93.4% at 30 days, 60 days, 90 days, and 120 days after the
sentinel node procedure was performed, respectively (see Table 4). A statistically significant
difference was noted when patients were stratified by region (Figure 3, p = 0.0061). In particular,
women in the Northeast region had consistently lower estimates at all of the time points when
compared to the overall cohort (38.9% vs 51.7% at 60 days, 77.9% vs 84.9% at 90 days).
However, by 120 days women in the Northeast seemed to catch up to the overall group 91.1% vs
93.4%.
When median time to Oncotype DX® was stratified by year of breast cancer diagnosis, a
significant difference was noted (Figure 4, p<0.0001). When year of breast cancer diagnosis was
increased by one (200720082009), a clear correlation can be seen in a decreased median
time to performing Oncotype DX®. In 2007, 3.2%, 40.6%, 76.6%, and 88.1% of patients had an
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Oncotype DX® performed at 30, 60, 90, and 120 days, respectively. By year 2009, those
numbers had increased to 5.9%, 61.4%, 91.4%, and 96.4%, respectively (Table 4).
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Table 1. Baseline demographics

Age
Mean (stdev)
Range (Min, Max)
Region
Midwest
Northeast
South
West
Year
2007
2008
2009

	
  

Oncotype Yes
(n=909)

Oncotype No
(n=1566)

p-value

52.9
23
N
235
113
403
158

(±7.77)
75
%
32.8%
36.3%
40%
35.9%

56.1
28
N
481
198
605
282

(±10.3)
87
%
67.2%
63.7%
60%
64.1%

<0.0001

286
403
220

27.7%
41.6%
46.7%

748
567
251

72.3%
58.5%
53.3%

<0.0001

11	
  

0.0240

Table 2. Characteristics of those receiving chemotherapy and logistic regression modeling the probability
of receiving adjuvant chemotherapy based on administration of Oncotype DX®, region, age, year of
diagnosis.

Age, years
Mean (stdev)
Range (Min, Max)
Region#
Midwest
Northeast
South
West
Year$
2007
2008
2009
Oncotype DX®
performed

Chemotherapy Yes
(n= 545)

Chemotherapy No
(n= 1930)

Adj.
OR
0.95

0.942 – 0.963

Adjusted
p-value
<0.0001*

51.7
23

(8.51)
82

55.9
25

(9.67)
87

194
38
221
92

27.1%
12.2%
21.9%
20.9%

522
273
787
348

72.9%
87.8%
78%
79.7%

1.31
0.47
--0.98

1.044 – 1.644
0.33 – 0.692
--0.74 – 1.30

0.02*
0.0001*
--0.894

247
202
96

23.9%
20.8%
20.4%

787
768
375

76.1%
79.2%
79.6%

--0.83
0.79

--0.66 – 1.03
0.60 – 1.04

--0.085
0.089

213

23.4%

696

76.6%

1.06

0.86 – 1.30

0.59

Abbreviations: Adj. OR, adjusted odds ratio; 95% CI, 95% confidence interval.
* Denotes adjusted odds ratio significantly different from one at P < .05.
# South selected as reference group.
$ 2007 selected as reference group.
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95% CI

Table 3. Characteristics of those that had Oncotype DX® performed and logistic regression modeling the
probability of administering Oncotype DX® prior to decision of chemotherapy performed controlling for
region, age, year of diagnosis

Age
Mean (stdev)
Range
(Min, Max)
Region#
Midwest
Northeast
South
West
Year$
2007
2008
2009

Oncotype Yes
(n=909)

Oncotype No
(n=1566)

52.9

±7.77

56.1

±10.3

23

75

28

87

235
113
403
158

32.8%
36.3%
40%
35.9%

481
198
605
282

67.2%
63.7%
60%
64.1%

286
403
220

27.7%
41.6%
46.7%

748
567
251

72.3%
58.5%
53.3%

Abbreviations: Adj. OR, adjusted odds ratio; 95% CI, 95% confidence interval
* Denotes adjusted odds ratio significantly different from one at P < .05.
# South selected as reference group.
$ 2007 selected as reference group.
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Adj.
OR
0.961

0.925 – 0.970

Adjusted
p-value
<0.0001*

0.71
0.894
--0.839

0.574 – 0.868
0.682 – 1.173
--0.66 – 1.065

0.001*
0.418
--0.149

--1.904
2.419

--1.574 – 2.304
1.919 – 3.049

--<0.0001*
<0.0001*

95% CI

Table 4. Kaplan-Meier estimates for time to utilization of Oncotype DX® by region and year of
diagnosis.

Overall
Region*
Midwest
Northeast
South
West
Year of diagnosis*
2007
2008
2009

30 days
(%)
4.4

(3.2 – 6)

60 days
(%)
51.7

2.6
3.5
6.5
2.5

(1.2 – 5.6)
(1.3 – 9.2)
(4.4 – 9.3)
(1 – 6.6)

3.2
4.5
5.9

(1.6 – 6)
(2.8 – 7)
(3.5 – 10)

95% CI

(48.5 – 55)

90 days
(%)
84.9

55.7
38.9
51.6
55.1

(49.5 – 62.2)
(30.6 – 48.6)
(46.8 – 56.6)
(47.5 – 62.9)

40.6
54.3
61.4

(35.1 – 46.5)
(49.6 – 59.3)
(55 – 67.8)

Abbreviations: 95% CI, 95% confidence interval
* Denotes log-rank test statistically significant at P<0.05.

95% CI

	
  

	
  

14	
  

(82.5 – 87.2)

120 days
(%)
93.4

(91.7 – 94.9)

90.2
77.9
81.1
91.8

(86 – 93.6)
(69.9 – 85)
(77.2 – 84.8)
(86.8 – 95.4)

95.3
91.1
91.6
96.8

(92.1 – 97.5)
(85 – 95.5)
(88.6 – 94)
(93.2 – 98.8)

76.6
87.3
91.4

(71.5 – 81.3)
(83.9 – 90.4)
(87.2 – 94.6)

88.1
95.5
96.4
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Figure 1. Pathway of inclusion/exclusion criteria.
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Figure 2. Proportion of patients receiving chemotherapy by Oncotype DX® yes/no
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Figure 3. Kaplan-Meier curves of time to Oncotype DX® by region.
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Figure 4. Kaplan-Meier curves of time to Oncotype DX® by year of diagnosis
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Section 4: Discussion/Conclusions

Our hypothesis that the use of Oncotype DX® would result in fewer women receiving chemotherapy
across the United States was not realized. The current study found that among women that had the
Oncotype DX® test performed, 23% received adjuvant chemotherapy compared to 21% of those without
an Oncotype DX® claim (p=0.1965). One potential explanation for this is that the individual RS was
unknown in the claims database. A multitude of studies have answered the question of whether the RS
from Oncotype DX® impacts both the clinician and/or patients’ decisions for adjuvant chemotherapy. In
an economic analysis from Israel, treatment decisions were collected prospectively before Oncotype
DX® was ordered for 313 patients (85% of those screened). 16 Overall, adjuvant chemotherapy was
recommended to 56% of patients before the RS was known, which decreased to 28% after the RS was
known. The percentage of patients reported to receive adjuvant chemotherapy is in line with findings
from the current study, in which 22% of patients received adjuvant chemotherapy. When Klang, et al.
stratified their sample by RS risk categories, the most marked change was in the low-risk group (RS <18)
where the recommendation went from 50% recommended to receive chemotherapy down to 0% actually
receiving chemotherapy. 16 In another study, 89 patients and their oncologists were surveyed about their
decisions for adjuvant treatment before and after the results of Oncotype DX®. Results from this study
indicate that 31.5% of decisions made by medical oncologists were changed and 27% of patients changed
their treatment decisions. 17 Both of these studies contrast the findings from the current study, most likely
due to the individual RS available for each patient that was not available in the claims database.
The current study demonstrated a significant impact of region on a patient’s odds of receiving adjuvant
chemotherapy: the adjusted odds ratio for patients in the Northeast was almost half (OR = 0.47 95% CI:
0.33 – 0.692) and about 31% higher for patients in the Midwest (OR = 1.31 95% CI: 1.047 – 1.649), with
the South as the reference region, controlling for all other variables. Previous research has explored
regional differences in a variety of breast cancer treatments including use of granulocyte colony
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stimulating factor21, compliance with locoregional standards of care22, rates of breast conserving
therapy23, and dose intensity of chemotherapy.24 A similarly constructed study looked at factors
associated with intentionally reduced doses of chemotherapy in breast cancer patients. 25 The authors
found in their multivariate analysis that geographic region, obesity status, and level of education
significantly affected when chemotherapy was “under-dosed,” or intentionally prescribed at less than 85%
of the recommended dose. 25 Interestingly, the geographic groups selected by these authors were very
similar to those in the current study, with the exception of the Midwest being called the Central region
and there were very similar distributions from each region in their study and the current study. Compared
to the Northeast region (their reference), the authors found that patients in the South were 5.6 times more
likely to have an intentionally reduced dose of chemotherapy. While these findings do not directly
confirm or refute the findings from the current study, which was focused on factors associated with
whether adjuvant chemotherapy was prescribed (i.e. Oncotype DX® , age, region, etc.) it does provide
information on regional differences and the potential effect of a “local treatment culture.” 26
Factors such as race, socioeconomic status, and education can affect compliance with guideline
recommendations in a variety of diseases, including breast cancer treatment. Per the most recent NCCN
guidelines, Oncotype DX® has a category 2B recommendation for early-stage, node-negative, hormone
receptor positive breast cancer if a patient’s tumor is >0.5 cm. 6 The current study, which attempted to
mirror the above population through inclusion and exclusion criteria, only noticed that 36.7% of these
“appropriate” patients received the Oncotype DX® test. What are the reasons for this seemingly low
uptake? One potential explanation may be the temporal issue of the time span of the claims database
(January 2007 to December 2009) and when Oncotype DX® became commercially available (2004). As
expected, the current study found that year of diagnosis was a significant determinant of receiving the
Oncotype DX® test (OR = 1.595 95% CI: 1.424 – 1.786), controlling for all other variables. So perhaps,
the effect we are seeing can be explained by a “lag time” in utilization of the test. Region did not have as
much of an impact on receiving the Oncotype DX® test as it did for the receipt of chemotherapy, as the
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ORs were lower. There was a significantly lower chance of receiving Oncotype DX® in the Midwest as
compared to the South (OR = 0.699 95% CI: 0.568 – 0.859), controlling for all other variables.
Time from the date of diagnosis of breast cancer to utilization of Oncotype DX® was also examined in
this study and yielded some interesting exploratory results. Looking at the Kaplan-Meier curve in Figure
3 provides evidence that when stratified by regions, the Midwest ordered the test sooner than other
regions at a median of slightly less than 60 days after diagnosis. Compare this to the Northeast, which
ordered the test around a median of 70 days after diagnosis. While this may not amount to a clinically
significant difference, a statistically significant difference exists among all regions (p=0.0061). However,
all regions seem to catch up with one another and approach 100% utilization of Oncotype DX® around
120 days. As expected, year of diagnosis was also significantly associated with the time to Oncotype
DX® test (p<0.0001, Figure 3).
A recent, large study examined the use of Oncotype DX® and adjuvant chemotherapy in the National
Comprehensive Cancer Network (NCCN) Breast Cancer Outcomes Database Project.

27

A stark contrast

between that study and the current study is that the authors did not restrict their cohort to early-stage,
node-negative breast cancer—they included all patients that had the test performed. The authors found a
smaller proportion of patients that received the test (20.4%) compared to the current study (36.7%), while
more women received adjuvant chemotherapy (50.2%) compared to the current study (22%).	
  27 This is
likely explained by their inclusion of women with more advanced disease. Interestingly, the authors did
demonstrate that chemotherapy use was lower among women that had the test performed compared to
those that did not (33% vs 54.7%, p<0.01). The authors also concluded in multivariate regression that
factors associated with a lower odds of receiving the test included: African American race (OR=0.70,
95% CI: 0.54 – 0.92) and an education of high school or less (OR=0.63, 95% CI: 0.52 – 0.76).	
  27 This
previous research confirms our findings of the increased utilization of Oncotype DX® over time.
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This is the first study, to the best of our knowledge, to explore the impact of exposure to Oncotype DX®
—not the output of the individual RS—on utilization of adjuvant chemotherapy in early-stage breast
cancer in an insurance claims-based model. This analysis provides insight on the frequency of the use of
Oncotype DX®, as well as the characteristics of the women in which the test is being utilized. It also
complements the work and confirms some of the findings of a larger, recent study. 27 The current study
is not without its limitations, however. The major disadvantage of the current analysis is the lack of the
RS. As previously mentioned, the RS has consistently shown to “downstage” patients overall and also
impact both prescribers’ and patients’ decisions for adjuvant chemotherapy. From a policy maker’s
perspective the current analysis provides evidence that use of Oncotype DX® does not significantly
reduce overall use of adjuvant chemotherapy. The second major weakness is our approach of using CPT
codes to define our patient sample. Undoubtedly, coding terminology changes and the way in which
procedures are “described” by combinations of CPT codes changes over time. Additionally, women were
excluded from the cohort if they had a more aggressive axillary lymph node dissection or mastectomy. A
lot of factors and personal experiences (shared family and friend experiences) go into a women’s decision
on primary surgical management of breast cancer. Some women opt for a more aggressive management
(bilateral prophylactic mastectomy, for example) even if their disease is low risk. These decisions cannot
be captured and measured reliably in a retrospective, claims-based database. The CPT definitions used
are accurate to the best of our ability at the time of preparing this manuscript. To help mitigate this
potential weakness, the lead author consulted with two medical oncologists specializing in breast cancer
on the most common terminologies and procedures performed in ESBC patients. Another weakness of
utilizing a claims database in the current analysis is the lack of clinicopathological features, such as tumor
size, nodal metastasis, and pathology reports that would have provided important information in the
decision for adjuvant chemotherapy. There was also limited to no demographic or comorbidity
information available in the current version of the claims database. Other missing data points like
comorbidity indices, race, socioeconomic status, zip code, etc. could have served as variables to help
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control for confounding in the current model. Perhaps in future updates of the database this question
could be posed again or in another database altogether linking more of these variables together.
In summary, Oncotype DX® does not significantly impact the number of women that are prescribed
adjuvant chemotherapy in a representative cohort of women with ESBC across the United States. In
multivariate analysis, significant predictors of decreasing the odds of receiving adjuvant chemotherapy
were age and residing in the Northeast. Residing in the Midwest significantly increased the odds of
receiving adjuvant chemotherapy. Year of diagnosis was not found to significantly affect the probability
of receiving adjuvant chemotherapy. Significant predictors of decreasing the odds of receiving an
Oncotype DX® test were age and residing in the Midwest. Later years of diagnosis were associated with
an increased odds of receiving an Oncotype DX® test.
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Appendix A. International Statistical Classification of Diseases and Health Related Problems-9 (ICD-9)
/Current Procedural Terminology (CPT) used to define early-stage, node-negative breast cancer patients.
Inclusion Criteria
ICD9 codes for breast cancer = 174.0 through 174.9
CPT 38792 (injection) + CPT 38500 (excision lymph node, superficial)
CPT 38792 (injection) + CPT 38525 (excision lymph node, deep axillary)
CPT 38792(injection) + CPT 38530 (excision, internal mammary)
Exclusion Criteria
CPT 19302 (partial lumpectomy + excision axillary lymph nodes)
CPT 19162 (mastectomy, partial; with axillary lymphadenectomy)
CPT 19305 (modified radical mastectomy)
CPT 19306 (mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph
nodes)
CPT 19307 (mastectomy, modified radical, including axillary dissection)
CPT 38740 (superficial axillary lymphadenectomy, removal all adipose tissue)
CPT 38745 (complete axillary lymphadenectomy)
	
  
Charges for Oncotype DX® were identified by the test’s unique CPT code (S3854).	
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Appendix B. National Drug Codes (NDCs) used to define hormonal therapy
Inclusion Criteria
Drug name
Anastrozole

Exemestane
Letrozole
Tamoxifen

	
  

NDCs
00054016413, 00093753656, 00378603405,
00378603477, 00781535631, 00904619546,
16571042103, 16729003510, 38779227406,
42043018003, 51079032301, 51079032306,
51991062010, 51991062033, 54569619800,
54868613000, 54868613001, 55111064730,
60258086603, 63275993001, 63275993002,
63323012930, 66435041530, 67877017110,
67877017130, 68084044811, 68084044821,
68382020906, 68382020910, 00310020130,
00310020137, 00310020150, 35356027030,
54569573100, 54868500000, 55175550503,
68258903501
00009766304, 49999098630, 54569573200,
54868526100
00078024915, 35356040930, 54569571400,
54868415100
00310060018, 00310060025, 00310060060,
00310060075, 00310060412, 00310060430,
00310060490, 53002103203, 54569038200,
54569038202, 54569853100, 55175550006,
55289058530, 57866661501, 57866661801,
58016065760, 60346004832, 13632012301,
00054483121, 00054483126, 00054483413,
00054483422, 00054883125, 00054883425,
00093078201, 00093078205, 00093078210,
00093078256, 00093078405, 00093078406,
00093078410, 00093078486, 00172565649,
00172565658, 00172565670, 00172565680,
00172565746, 00172565755, 00172565760,
00172565770, 00172565780, 00310073060,
00310073130, 00378014405, 00378014491,
00378027401, 00378027493, 00440845030,
00440845060, 00440845092, 00440845130,
00440845160, 00440845192, 00555044603,
00555044605, 00555044609, 00555044663,
00555090401, 00555090405, 00555090414,
00591223218, 00591223260, 00591223319,
00591223330, 38779034101, 38779034103,
38779034104, 38779034105, 38779034108,
49452775301, 51552083802, 51927297600,
54569376500, 54569376501, 54569571600,
54569860200, 54868300401, 54868300402,
54868300403, 54868300404, 54868300405,

25	
  

54868428700, 54868428701, 54868428702,
54868428703, 54868428704, 63304060028,
63304060060, 63304060130, 63304060190,
63739026910, 63739026915
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Appendix C. J-codes used to define chemotherapy
Inclusion Criteria
Drug name
Cyclophosphamide Oral 25 MG
Cyclophosphamide 100 MG Inj.
Cyclophosphamide 200 MG Inj.
Cyclophosphamide 500 MG Inj.
Cyclophosphamide 1 G Inj.
Cyclophosphamide 2 G Inj.
Cyclophosphamide Lyophilized 100 MG Inj.
Cyclophosphamide Lyophilized 200 MG Inj.
Cyclophosphamide Lyophilized 500 MG Inj.
Cyclophosphamide Lyophilized 1 G Inj.
Cyclophosphamide Lyophilized 2 G Inj.
Doxorubicin HCL 10 MG Inj.
Doxorubicin HCL LIPID 10 MG Inj.
Docetaxel 20 MG Inj.
Docetaxel 1 MG Inj.
Epirubicin HCL 2 MG Inj.
Epirubicin HCL Inj.
Fluorouracil 500 MG Inj.
Methotrexate Oral 2.5 MG
Methotrexate Sodium 5 MG Inj.
Methotrexate Sodium 50 MG Inj.
Paclitaxel Protein Bound Particle 1 MG Inj.
Paclitaxel 30 MG Inj.

J-code
J8530
J9070
J9080
J9090
J9091
J9092
J9093
J9094
J9095
J9096
J9097
J9000
J9001
J9170
J9171
J9178
J9180
J9190
J8610
J9250
J9260
J9264
J9265

Exclusion Criteria
Trastuzumab

J9355
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Appendix D. NDCs used to define chemotherapy
Inclusion Criteria
Cyclophosphamide

Doxorubicin

Docetaxel
Doxorubicin HCl liposomal
Epirubicin

	
  

00054412925, 00054413025, 00054808925,
00054813025, 10019095501, 10019095550,
10019095601, 10019095616, 10019095701,
10019095711, 38779050603, 54569571200,
54569571300, 54868500500, 54868500501,
54868521800, 54868521801, 54868521802,
00015050041, 00015050141, 00015050241,
00015050301, 00015050302, 00015050401,
00015050541, 00015050641, 00087050001,
00015053941, 00015054641, 00015054712,
00015054741, 00015054812, 00015054841,
00015054912, 00015054941, 00013560693,
00013561693, 00013562693, 00013564670,
00013563670
55390023110, 55390023210, 55390023301,
55390023510, 55390023610, 55390023701,
55390023801, 00013108691, 00013109691,
00013109694, 00013110679, 00013111683,
54868313100, 00013113691, 00013114691,
00013114694, 00013115679, 00013116683,
00013117687, 00013123691, 00013124691,
00013125679, 00013126683, 00013128683,
00074504001, 00074504303, 00074504601,
00186153013, 00186153101, 00186153231,
00186153241, 00186153261, 00186153281,
00186157512, 00469100161, 00469883020,
00469883130, 00469883250, 00702023110,
00702023206, 00702023301, 00702023510,
00702023606, 00702023610, 00702023701,
00702023801, 00703504001, 00703504303,
00703504601, 10019092001, 10019092102,
53905023110, 53905023210, 53905023301,
53905023510, 53905023610, 53905023701,
53905023801, 55390024110, 55390024210,
55390024301, 55390024510, 55390024610,
55390024701, 55390024801, 63323010161,
63323088305, 63323088310, 63323088330,
00015335122, 00015335222, 00015335322
00075800120, 00075800180, 00075800301,
00075800404
17314960001, 17314960002, 61471029512
00009509101, 00009509301, 00591346983,
00591347057, 00703306711, 00703306911,
10139006101, 10139006125, 10518010410,
10518010411, 25021020325, 25021020351,
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Fluorouracil

Methotrexate

	
  

55390020701, 55390020801, 59762509101,
59762509301, 61703034735, 61703034859,
61703035901, 61703035902, 61703035959,
61703035991, 61703035992, 61703035993,
63323015100, 63323015105, 63323015125,
63323015175, 66758004201, 66758004202,
00013103691, 00013104694, 00013105694,
00703301513, 00703301812, 00703301912,
00066715030, 54868545000, 00004150603,
00004170406, 00004170506, 00187320202,
00187320210, 00187320302, 00187320310,
00187320426, 00187320447, 54569110000,
54569156600, 54868095100, 54868095101,
58016201701, 00023081030, 00023081230,
54569156500, 55045210308, 58016910601,
00004197701, 00187395364, 10019095002,
10139006301, 10139006310, 10139006311,
10139006312, 10139006320, 10139006350,
38779002501, 38779002504, 38779002505,
38779002509, 38779002510, 38779002525,
39769001210, 39769001290, 43547025801,
43547025901, 49452317501, 49452317502,
49452317503, 49452317504, 51552073301,
51552073302, 51552073304, 51552073305,
51672406201, 51672406301, 51672411806,
51927108500, 61703040932, 61703040953,
61703040967, 62991148602, 63323011710,
63323011720, 63323011751, 63323011761,
63370009515, 63370009525, 63370009535,
66530024940, 66758004401, 66758004403,
68682000431, 68682008531
00013229691, 00013226691, 00013227691,
00013228691, 38779003503, 38779003504,
38779003506, 38779003510, 38779003511,
38779003515, 38779003525, 49452460001,
49452460002, 49452460003, 49452460101,
49452460102, 49452460103, 49452460104,
51552105401, 51552105409, 51927156500,
62991120001, 62991120002, 63370015410,
63370015415, 63370015425, 00005450723,
00054455015, 00054455025, 00054855003,
00054855005, 00054855006, 00054855007,
00054855010, 00054855025, 00182153901,
00182153995, 00364249901, 00364249936,
00378001401, 00378001450, 00405464301,
00405464336, 00536399801, 00536399836,
00555057202, 00555057235, 00555057245,
00555057246, 00555057247, 00555057248,
29	
  

Paclitaxel

	
  

00555057249, 00603449921, 00677161001,
00781107601, 00781107636, 00839790506,
00904174960, 00904174973, 00904601260,
11845110401, 21695011100, 23490588900,
49999038024, 49999038036, 51079067001,
51079067005, 51079067086, 51079067087,
51079067088, 51079067089, 51285050902,
52959024400, 53002048720, 54569181800,
54569181803, 54569181809, 54868382600,
54868382601, 54868382602, 54868382603,
54868382604, 54868382605, 54868382606,
54868382607, 54868382608, 54868382609,
54868479600, 55289092430, 59911587401,
61703035038, 61703040822, 62584078201,
62701094036, 62701094099, 63323012302,
63323012310, 63629147201, 63629147202,
66479013501, 66479013509, 67253032010,
67253032036, 68115063200, 10139006202,
10139006210, 10139006240, 54868017301,
54868471600, 55390003110, 55390003210,
55390003310, 55390003410, 55390014301,
61703040841, 63323012102, 63323012104,
63323012108, 63323012110, 63323012140,
63323012250, 66479013611, 66479013721,
66479013929, 66758004001, 66758004002,
66758004008, 66758004101, 00205532526,
00205532618, 00205532730, 00205533734,
54569452500, 58406068312, 58406068315,
58406068316, 58406068318, 66479013613,
66479013619, 10019094101, 53905003110,
53905003210, 53905003310, 53905003410,
54569531600, 61703040707, 61703040732,
61703040858, 10019094001, 10019094002,
61703040804, 61703040807, 61703040813,
61703040832, 00205455626, 00205465302,
00205465490, 00205533834, 00205933792,
58406067101, 58406067103, 58406068114,
58406068117, 58406067105, 58406067301,
00005450704, 00005450705, 00005450707,
00005450709, 00005450791, 67253058042
67253058043, 67253058044, 67253058045,
67253058046, 00555092701, 00555092801,
00555092901, 00555094501, 51285036601,
51285036701, 51285036801, 51285036901
00015345620, 00015345699, 00015347520,
00015347527, 00015347530, 00015347620,
00015347627, 00015347630, 00015347911,
00172375377, 00172375396, 00172375473,
30	
  

Paclitaxel Protein-Bound

00172375494, 00172375531, 00172375576,
00172375675, 00172375695, 00074433501,
00074433502, 00074433504, 00555198414,
00555198514, 00703476401, 00703476601,
00703476701, 00703476801, 10518010207,
10518010208, 10518010209, 51079096101,
51079096201, 51079096301, 55390011405,
55390011420, 55390011450, 55390030405,
55390030420, 55390030450, 55390031405,
55390031420, 55390031450, 55390051405,
55390051420, 55390051450, 61703034209,
61703034222, 61703034250, 63323076305,
63323076316, 63323076350, 66758004301,
66758004302, 66758004303
68817013450

Exclusion Criteria
Trastuzumab

50242005656, 50242013460, 50242013468
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Appendix E. States used in regional breakdown
U.S. Census Bureau Regions
Connecticut
Maine
Massachusetts
New Hampshire
Rhode Island
Indiana
Illinois
Michigan
Ohio
Wisconsin
Iowa
Delaware
District of Columbia
Florida
Georgia
Maryland
North Carolina
South Carolina
Virginia
West Virginia
Arizona
Colorado
Idaho
New Mexico
Montana
Utah
Nevada

Northeast
New Jersey
New York
Pennsylvania
Vermont
Midwest
Nebraska
Kansas
North Dakota
Minnesota
South Dakota
Missouri
South
Alabama
Kentucky
Mississippi
Tennessee
Arkansas
Louisiana
Oklahoma
Texas
West
Alaska
California
Hawaii
Oregon
Washington
Wyoming

Adapted from Census Regions and Divisions of the United States. (Accessed at
http://www.census.gov/geo/www/us_regdiv.pdf.)
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